Related Experiment Videos
Interferon-beta induces the development of type 2 dendritic cells
Y M Huang1, Y Hussien, D Yarilin
1Neuroimmunology Unit, Division of Neurology, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden. yu-min.huang@neurotec.ki.se
Cytokine
|March 13, 2001
Summary
Interferon (IFN)-beta treatment for multiple sclerosis (MS) may work by altering dendritic cells (DCs). IFN-beta induces DCs to produce more IL-10 and less IL-12, potentially promoting Th2 immune responses.
Area of Science:
- Immunology
- Neuroscience
- Cell Biology
Background:
- Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease with potential autoimmune origins.
- Interferon (IFN)-beta is a treatment for MS, and its mechanism is thought to involve suppression of interleukin (IL)-12 production by dendritic cells (DCs).
- The precise interaction between IFN-beta and DCs to inhibit IL-12 production is not fully understood.
Purpose of the Study:
- To investigate how IFN-beta influences the differentiation and function of human dendritic cells (DCs).
- To elucidate the mechanism by which IFN-beta affects IL-12 production in DCs.
- To explore the potential role of IFN-beta-induced DC changes in the immunomodulation relevant to MS treatment.
Main Methods:
- Human peripheral blood monocytes were cultured with IFN-beta, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-4 to differentiate into DCs.
- Flow cytometry was used to analyze DC surface marker expression, including CD14, CD1a, HLA-DR, and CD123 (IL-3Ralpha).
- Cytokine production (IL-10, IL-12p40, IFN-gamma) by DCs and their effect on allogeneic blood mononuclear cells were assessed.
Main Results:
- IFN-beta induced differentiation of monocytes into DCs expressing IL-3Ralpha (CD123) while downregulating CD1a.
- IFN-beta treatment led to the maturation of IL-3Ralpha+ DCs, characterized by increased HLA-DR, CD40, CD80, and CD86 expression.
- IFN-beta-treated DCs produced significantly lower levels of IL-12p40 and higher levels of IL-10 compared to control DCs, suppressing IFN-gamma and enhancing IL-10 production by T cells.
Conclusions:
- In vitro, IFN-beta promotes the development of a specific DC subset (DC2) characterized by IL-3Ralpha expression.
- These IFN-beta-induced DCs exhibit an immunomodulatory profile, favoring IL-10 production and potentially Th2 cell differentiation.
- This study reveals a novel mechanism for IFN-beta's action in MS, involving the induction of tolerogenic DCs that may suppress pro-inflammatory responses.